99 Wall Street, Suite 232, New York, NY 10005

Need Help? Call : (800) 991-3756

Class Action Cases

A class action has been filed on behalf of BLUE Investors. Click "Join this Class Action" above.

Attorneys

bluebird bio, Inc.

Join Class Action »

Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of bluebird bio, Inc. (NASDAQ: BLUE) from May 11, 2020 through November 4, 2020 (the “Class Period”). The lawsuit seeks to recover damages for bluebird bio, Inc. investors under the federal securities laws.

If you bought bluebird bio, Inc. securities between May 11, 2020 through November 4, 2020, and would like to join the action, please click “Join This Class Action,” above.

Press Release

SHAREHOLDER ALERT: Zhang Investor Law Announces a Securities Class Action Lawsuit Against bluebird bio, Inc. – BLUE

New York, N.Y., February 19, 2021. Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of bluebird bio, Inc. (NASDAQ:BLUE) between May 11, 2020 and November 4, 2020, inclusive (the “Class Period”).

To join the BLUE class action, go to http://zhanginvestorlaw.com/cases/bluebird-bio-inc/ call Sophie Zhang, Esq. toll-free at 800-991-3756 or email info@zhanginvestorlaw.com for information on the class action.

Lead plaintiff status is not required to seek compensation. You may retain counsel of your choice. You may remain an absent class member and take no action at this time.

According to the lawsuit,  throughout the Class Period (1) data supporting bluebird’s U.S. Biologics Licensing Application (“BLA”) submission for LentiGlobin for sickle cell disease (“SCD”) was insufficient to demonstrate drug product comparability; (2) defendants downplayed the foreseeable impact of disruptions related to the COVID-19 pandemic on the Company’s BLA submission schedule for LentiGlobin for SCD, particularly with respect to manufacturing; (3) as a result of all the foregoing, it was foreseeable that the Company would not submit the BLA for LentiGlobin for SCD in the second half of 2021; and (4) as a result, the Company’s public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 13, 2021. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://zhanginvestorlaw.com/cases/bluebird-bio-inc/ or to discuss your rights or interests regarding this class action, please contact Sophie Zhang, Esq. of Zhang Investor Law toll free at 800-991-3756 or via e-mail at info@zhanginvestorlaw.com.

Zhang Investor Law represents investors worldwide.